Literature DB >> 23231711

Risk stratification for invasive aspergillosis in immunocompromised patients.

Raoul Herbrecht1, Pierre Bories, Jean-Charles Moulin, Marie-Pierre Ledoux, Valérie Letscher-Bru.   

Abstract

Severe prolonged neutropenia, allogeneic hematopoietic stem cell or solid-organ transplantation, corticosteroids or other T cell suppressive agents, and other severe immunosuppressive factors have for many years been considered to predispose patients to invasive aspergillosis. Other conditions such as impaired innate immunity, diabetes, renal impairment, progression of the underlying malignancy, prior respiratory disease, and nosocomial or environmental exposure to fungal spores or climatic factors have recently been considered additional risk factors of invasive aspergillosis. The multiplicity of risk factors as well as the obvious synergy between them renders risk stratification difficult. An international, large-scale, multicenter, epidemiological study is necessary to develop a risk score.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23231711     DOI: 10.1111/j.1749-6632.2012.06829.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  37 in total

1.  A fatal case of cerebral aspergillosis in a diabetes mellitus patient.

Authors:  Xiaohui Liu; Wanrun Lin; Yongxiang Wang; Zhou Wang; Yifeng Du
Journal:  Neurol Sci       Date:  2015-05-19       Impact factor: 3.307

Review 2.  Treatment principles for the management of mold infections.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

3.  Serious fungal infections in Portugal.

Authors:  R Sabino; C Verissímo; J Brandão; C Martins; D Alves; C Pais; D W Denning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-10       Impact factor: 3.267

4.  Invasive aspergillosis in neutropenic patients during hospital renovation: effectiveness of mechanical preventive measures in a prospective cohort of 438 patients.

Authors:  Michael Loschi; Caroline Thill; Christian Gray; Marion David; Marie-France Bagatha; Ali Chamseddine; Nathalie Contentin; Fabrice Jardin; Helene Lanic; Emilie Lemasle; Pascal Lenain; Aspasia Stamatoullas; Hervé Tilly; Stephane Lepretre
Journal:  Mycopathologia       Date:  2015-01-31       Impact factor: 2.574

5.  Reply to "Risk for invasive fungal infections during acute myeloid leukemia induction therapy: a true association with echinocandins?".

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2014-08       Impact factor: 5.191

6.  Chronic Invasive Aspergillus Sinusitis and Otitis with Meningeal Extension Successfully Treated with Voriconazole.

Authors:  Marjolaine Morgand; Blandine Rammaert; Sylvain Poirée; Marie-Elisabeth Bougnoux; Hugo Tran; Romain Kania; Fabrice Chrétien; Gregory Jouvion; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

7.  Dectin-1 rs3901533 and rs7309123 Polymorphisms Increase Susceptibility to Pulmonary Invasive Fungal Disease in Patients with Acute Myeloid Leukemia from a Chinese Han Population.

Authors:  Mei-Jing Chen; Rong Hu; Xiao-Ying Jiang; Yong Wu; Zhi-Peng He; Jing-Yi Chen; Li Zhan
Journal:  Curr Med Sci       Date:  2019-12-16

8.  An estimate of the burden of serious fungal diseases in Greece.

Authors:  M N Gamaletsou; M Drogari-Apiranthitou; D W Denning; N V Sipsas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-16       Impact factor: 3.267

Review 9.  Aspergillus fumigatus and Aspergillosis in 2019.

Authors:  Jean-Paul Latgé; Georgios Chamilos
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

Review 10.  Lichtheimia Infection in a Lymphoma Patient: Case Report and a Brief Review of the Available Diagnostic Tools.

Authors:  Stefan Zimmerli; Ralf Bialek; Igor W Blau; Andreas Christe; Cornelia Lass-Flörl; Elisabeth Presterl
Journal:  Mycopathologia       Date:  2016-04-26       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.